1. HBW Insight
  2. >>Wellness
  3. >>Policy & Regulation
  4. >>Recalls

US Consumer Health Regulation: Before Warning, Recall For Supplement With COVID-19 Label Claim

 
• By Malcolm Spicer

Until FDA on 23 June posted report about Golden Nutrition Inc.’s herbal supplement, violative COVID-19 claims had been found online and in advertising through other channels. Other consumer health recalls in US include more than 2.5m bottles of Gaviscon Liquid Antacid missing a safety warning on labels.

Attention Please_1014394012_1200.jpg

Posting unlawful claims online for treating or preventing COVID-19 will prompt regulatory warnings in the US, but using those claims on product labels will lead to a recall, as a Florida firm learned recently.

Additional consumer health products on recall in the US include more than 2.5m bottles of Gaviscon Liquid Antacid missing a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Recalls

Old Problem Of Drugs In Supplements Welcomes US FDA’s Acting Food Chief To New Program

 
• By Malcolm Spicer

Kyle Diamantas was a partner with the Jones Day firm when he was tabbed as acting deputy commissioner to lead the FDA’s Human Foods Program, established in the agency’s reorganization which became effective in October.

Reporting Problems To US FDA Simplified After Delayed Response To Formula Plant Complaint

 
• By Malcolm Spicer

Streamlined process for reporting problems is key piece of “unified Human Foods Program” which officially launched on 1 October, as Commissioner Robert Califf says, “a new model for field operations and other modernization efforts.”

US Formula Market Astir With Changes As Congress Stirs Tighter Product Quality Regulations

 
• By Malcolm Spicer

Brands also making market moves as lawmakers consider legislation instructing Transportation Security Administration to provide guidance to minimize risk for contamination of baby formula and related pediatric nutritional products.

Different Name, Same Contamination, Recall Problems For US Homeopathic Nasal Spray Firm

 
• By Malcolm Spicer

Green Pharmaceuticals’ SnoreStop Nasal Spray, previously marketed as “NasoSpray,” still is available even though agency officials on multiple occasions for a month recommended a recall after an April inspection found “gross microbial contamination” in one lot.

More from Policy & Regulation

FDA RIF Delays Response On NPA NMN Petition

 
• By Malcolm Spicer

Due to staff reductions at FDA ordered by DOGE, but accounting for return of some employees after their dismissals were rescinded, agency missed July 31 deadline it had set for responding to the NPA’s petition and expects to respond by Sept. 30.

US FDA’s Kratom Focus Pivots To ‘Concentrated Synthetic Byproduct That Is An Opioid’

 
• By Malcolm Spicer

Explaining he was a heroin addict for 14 years more than 40 years ago “because it was so available,” Secretary Kennedy says “our agencies have been asleep in the wheel” but “now we're going to wake up and we're going to start to stop this before it starts.”

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By David Ridley

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.